Non-Invasive Prenatal Testing for trisomies 21, 18 and 13 (NIPT)

The prenatal trisomy screening test based on a simple maternal blood sample
Ninalia NIPT: at a glance

- NIPT stands for Non-Invasive Prenatal Testing
- No risk to foetus since this test requires a simple blood draw from the mother.
- Ninalia can detect if the foetus is affected by trisomy 21, 18 or 13

Advantages of Ninalia

Simple 1
Single blood sample

Safe 95%
Can minimize unnecessary invasive sampling by 95% and thus reduce the associated risk to the foetus*

Early 10
Available from week 10 of pregnancy, right after 1st trimester maternal serum markers screening

Accurate 99%
Detection rate of Ninalia test

Ninalia screening test is performed and interpreted by qualified prenatal geneticists

* Non-invasive prenatal testing of trisomies 21, 18 and 13 could make 95% of invasive tests, with an associated risk of miscarriage of around 0.5 to 1%, redundant (source: French National College of Gynaecologists and Obstetricians (CNGOF))
Understanding the results provided by your healthcare provider

- A positive result indicates a strong suspicion that the foetus is affected by trisomy 21, 18 or 13
- A negative result indicates an extremely low risk but does not completely rule out the presence of the anomaly.
- Your healthcare provider, supported by Eurofins Biomnis prenatal experts, will explain the results to you and discuss the appropriate actions to take, if necessary.

Step by step guide to Ninalia

From 10 weeks (gestational age) 1 single blood draw

Medical consultation and Ninalia prescription

Sample collection by the healthcare provider

Analysis of the main foetal aneuploidies: trisomies 21, 18 and 13

Shipment of the blood sample to Eurofins Biomnis France

Results sent to healthcare prescriber within 5 business days*

* For example, if the sample is received in Eurofins Biomnis on a Tuesday, the results will be sent to your healthcare provider the following Monday

If you have any further questions, please ask your healthcare provider.
About Eurofins Biomnis

Eurofins Biomnis, European leader in specialised medical pathology, has its origins in the laboratory established by Marcel Mérieux in 1897. Its primary focus is the performance of highly specialised analyses requiring the use of high-expertise test procedures.

Eurofins Biomnis is active in all fields of medical pathology, in particular foetal biochemistry and prenatal diagnostics.

Geneticists, qualified in prenatal diagnosis and responsible for Eurofins Biomnis tests are available to prescribers to provide the best possible support in the implementation of this genetic test.

To know more about Ninalia and to order the kit, please visit: www.nipt-biomnis.com